131 related articles for article (PubMed ID: 34262621)
1. Comparison of healthcare resource utilization and medical costs between patients with seropositive and seronegative rheumatoid arthritis.
Kim H; Cho SK; Choi S; Im SG; Jung SY; Jang EJ; Sung YK
Ther Adv Musculoskelet Dis; 2021; 13():1759720X211024830. PubMed ID: 34262621
[TBL] [Abstract][Full Text] [Related]
2. Clinical management of seronegative and seropositive rheumatoid arthritis: A comparative study.
Choi S; Lee KH
PLoS One; 2018; 13(4):e0195550. PubMed ID: 29624625
[TBL] [Abstract][Full Text] [Related]
3. Differing X-ray patterns in seronegative and seropositive rheumatoid arthritis.
Gadeholt O; Hausotter K; Eberle H; Klink T; Pfeil A
Clin Rheumatol; 2019 Sep; 38(9):2403-2410. PubMed ID: 31123977
[TBL] [Abstract][Full Text] [Related]
4. Seasonal distribution of relapse onset in rheumatoid arthritis and spondyloarthropathy: the possible effect of the solar factor.
Rozin A; Balbir-Gurman A; Schapira D
Clin Exp Rheumatol; 2003; 21(2):161-9. PubMed ID: 12747269
[TBL] [Abstract][Full Text] [Related]
5. Rheumatoid Arthritis and Risk of Parkinson Disease in Korea.
Kang J; Eun Y; Jang W; Cho MH; Han K; Jung J; Kim Y; Kim GT; Shin DW; Kim H
JAMA Neurol; 2023 Jun; 80(6):634-641. PubMed ID: 37126341
[TBL] [Abstract][Full Text] [Related]
6. iTRAQ-based proteomic analysis of differentially expressed proteins in sera of seronegative and seropositive rheumatoid arthritis patients.
He Y; Lin J; Tang J; Yu Z; Ou Q; Lin J
J Clin Lab Anal; 2022 Jan; 36(1):e24133. PubMed ID: 34812532
[TBL] [Abstract][Full Text] [Related]
7. A comparative study on the clinical and magnetic resonance imaging features between seronegative and seropositive rheumatoid arthritis.
Mo Q; Wang M; Cai S; Zhong J; Dong L
Clin Exp Rheumatol; 2024 Jan; 42(1):77-85. PubMed ID: 37470243
[TBL] [Abstract][Full Text] [Related]
8. Rheumatoid Arthritis and Risk of Depression in South Korea.
Jeon KH; Han K; Jung J; Park CI; Eun Y; Shin DW; Kim H
JAMA Netw Open; 2024 Mar; 7(3):e241139. PubMed ID: 38441894
[TBL] [Abstract][Full Text] [Related]
9. Impact of Rheumatoid Arthritis and Seropositivity on the Risk of Non-Cystic Fibrosis Bronchiectasis.
Choi H; Han K; Jung JH; Park J; Kim BG; Yang B; Eun Y; Kim H; Shin DW; Lee H
Chest; 2024 Jun; 165(6):1330-1340. PubMed ID: 38184167
[TBL] [Abstract][Full Text] [Related]
10. The Impact of Seropositivity on Systemic Bone Loss in Rheumatoid Arthritis-A 3-Year Interim Analysis of a Longitudinal Observational Cohort Study.
Yu SF; Chen JF; Chen YC; Wang YW; Hsu CY; Lai HM; He HR; Ko CH; Chiu WC; Cheng TT
Front Med (Lausanne); 2022; 9():885801. PubMed ID: 35755026
[TBL] [Abstract][Full Text] [Related]
11. Healthcare resource utilization and costs among patients with rheumatoid arthritis on biologic therapies in Taiwan: A 1-year mirror-image study using a national claims database.
Chen KC; Wu CH; Tang CH; Huang KC
PLoS One; 2018; 13(7):e0200758. PubMed ID: 30020997
[TBL] [Abstract][Full Text] [Related]
12. Influence of anti-carbamylated protein antibodies on disease activity and joint erosions in seronegative and seropositive rheumatoid arthritis.
Amezcua-Guerra LM; Carbonell-Bobadilla N; Soto-Fajardo C; Vargas A; Batres-Marroquín AB; Vargas T; Medina-García AC; Hernández-Diazcouder A; Jiménez-Rojas V; Pineda C; Silveira LH
Rheumatol Int; 2023 Dec; 43(12):2245-2250. PubMed ID: 37697044
[TBL] [Abstract][Full Text] [Related]
13. In vitro IgM rheumatoid factor production by peripheral blood mononuclear cells from patients with seronegative rheumatoid arthritis.
Nonaka S; Yasuda M; Nobunaga M
J Rheumatol; 1993 Sep; 20(9):1478-84. PubMed ID: 7513025
[TBL] [Abstract][Full Text] [Related]
14. Utilization and costs of medical services and prescription medications for rheumatoid arthritis among recipients covered by a state Medicaid program: a retrospective, cross-sectional, descriptive, database analysis.
Khanna R; Smith MJ
Clin Ther; 2007 Nov; 29(11):2456-67. PubMed ID: 18158087
[TBL] [Abstract][Full Text] [Related]
15. Health Care Resource Utilization and Costs Associated With Switching Biologics in Rheumatoid Arthritis.
Vanderpoel J; Tkacz J; Brady BL; Ellis L
Clin Ther; 2019 Jun; 41(6):1080-1089.e5. PubMed ID: 31122662
[TBL] [Abstract][Full Text] [Related]
16. Analysis of Serum Immune Markers in Seropositive and Seronegative Rheumatoid Arthritis Among Sudanese Patients and the Relation Between the Serotype and Joint Involvement: A Cohort Study.
Seri A; Kamal Ali Mohamed H; Adam Essa ME; Elagib EM; Eltahirm NIA; Mansour SMA; Ahmed AA
Open Access Rheumatol; 2021; 13():325-332. PubMed ID: 34876862
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Switching to a Non-Tumor Necrosis Factor Inhibitor Versus a Tumor Necrosis Factor Inhibitor Biologic Therapy among Patients with Rheumatoid Arthritis.
Zhou ZY; Griffith J; Du EX; Chin D; Betts KA; Ganguli A
Adv Ther; 2016 May; 33(5):807-23. PubMed ID: 27084724
[TBL] [Abstract][Full Text] [Related]
18. Medical costs for Korean patients with rheumatoid arthritis based on the national claims database.
Kwon JM; Cho SK; Kim JH; Lee EK
Rheumatol Int; 2012 Sep; 32(9):2893-9. PubMed ID: 21898062
[TBL] [Abstract][Full Text] [Related]
19. Comparison of Healthcare Utilization and Costs Between RA Patients Receiving Biological and Conventional Synthetic DMARDs: A Nationwide Population-Based Cohort Study in Taiwan.
Chen DY; Yu F; Tuan LW; Tang CH
Front Pharmacol; 2019; 10():1214. PubMed ID: 31695611
[No Abstract] [Full Text] [Related]
20. Changes in utilization and costs for patients with rheumatoid arthritis, 1997 to 2006.
Birnbaum HG; Pike C; Banerjee R; Waldman T; Cifaldi M
Pharmacoeconomics; 2012 Apr; 30(4):323-36. PubMed ID: 22379953
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
